272 related articles for article (PubMed ID: 25263539)
1. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
Smith MA; Hampton OA; Reynolds CP; Kang MH; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Kurmasheva RT; Wheeler DA; Houghton PJ
Pediatr Blood Cancer; 2015 Jan; 62(1):91-8. PubMed ID: 25263539
[TBL] [Abstract][Full Text] [Related]
2. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
Smith MA; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Carol H; Lock RB; Keir ST; Maris JM; Billups CA; Lyalin D; Kurmasheva RT; Houghton PJ
Clin Cancer Res; 2015 Feb; 21(4):819-32. PubMed ID: 25500058
[TBL] [Abstract][Full Text] [Related]
3. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
[TBL] [Abstract][Full Text] [Related]
4. Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.
Kurmasheva RT; Reynolds CP; Kang MH; Allievi C; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 May; 61(5):922-4. PubMed ID: 24166988
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
Norris RE; Adamson PC; Nguyen VT; Fox E
Pediatr Blood Cancer; 2014 Jan; 61(1):145-50. PubMed ID: 24038812
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
Wilkerson PM; Dedes KJ; Samartzis EP; Dedes I; Lambros MB; Natrajan R; Gauthier A; Piscuoglio S; Töpfer C; Vukovic V; Daley F; Weigelt B; Reis-Filho JS
Oncotarget; 2017 Jan; 8(4):6057-6066. PubMed ID: 28002809
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells.
Sethy C; Kundu CN
Toxicol Appl Pharmacol; 2022 Feb; 436():115860. PubMed ID: 34998856
[TBL] [Abstract][Full Text] [Related]
8. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Cardnell RJ; Feng Y; Diao L; Fan YH; Masrorpour F; Wang J; Shen Y; Mills GB; Minna JD; Heymach JV; Byers LA
Clin Cancer Res; 2013 Nov; 19(22):6322-8. PubMed ID: 24077350
[TBL] [Abstract][Full Text] [Related]
9. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.
Shen Y; Rehman FL; Feng Y; Boshuizen J; Bajrami I; Elliott R; Wang B; Lord CJ; Post LE; Ashworth A
Clin Cancer Res; 2013 Sep; 19(18):5003-15. PubMed ID: 23881923
[TBL] [Abstract][Full Text] [Related]
10. The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer.
Huang J; Wang L; Cong Z; Amoozgar Z; Kiner E; Xing D; Orsulic S; Matulonis U; Goldberg MS
Biochem Biophys Res Commun; 2015 Aug; 463(4):551-6. PubMed ID: 26047697
[TBL] [Abstract][Full Text] [Related]
11. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438
[TBL] [Abstract][Full Text] [Related]
12. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
13. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
Carol H; Lock R; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2009 Dec; 53(7):1255-63. PubMed ID: 19554570
[TBL] [Abstract][Full Text] [Related]
14. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program.
Houghton PJ; Morton CL; Kang M; Reynolds CP; Billups CA; Favours E; Payne-Turner D; Tucker C; Smith MA
Pediatr Blood Cancer; 2010 Dec; 55(6):1224-6. PubMed ID: 20979180
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone.
Aoyagi-Scharber M; Gardberg AS; Yip BK; Wang B; Shen Y; Fitzpatrick PA
Acta Crystallogr F Struct Biol Commun; 2014 Sep; 70(Pt 9):1143-9. PubMed ID: 25195882
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
Choy E; Butrynski JE; Harmon DC; Morgan JA; George S; Wagner AJ; D'Adamo D; Cote GM; Flamand Y; Benes CH; Haber DA; Baselga JM; Demetri GD
BMC Cancer; 2014 Nov; 14():813. PubMed ID: 25374341
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
20. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]